|
?
?
Go!
Posting Rules
All times are GMT -5. The time now is 06:58 PM.
seattle weather skier sarah burke gingrich wife cheryl burke sarah burke mega upload santorum wins iowa
Sunday, April 1, 2012
GDT: Game 79 | Florida Panthers @ Detroit Red Wings | 4:00 PM EST |FSD (HD)|NHLN
Survey: One in Three Families in America Has ... - Finance Help News
Survey: One in Three Families in America Has Trouble Paying Medical Bills
Personal bankruptcies seem to be on a rise plus the number could grow higher using the new Obamacare mandates. The recession has hit many Americans hard. People struggling to cover bills have used credit cards to help. As a result, they now have created debt on high-interest cards and no longer manage to make even minimum monthly bills. As a conclusion, they have been declaring personal bankruptcy, in fact it is typically a final option. And new laws requiring that all of us carry health insurance has forced some to file a lawsuit. This article has been shared by Kaplan Attorneys. You can find Kaplan Attorneys by searching for Massachusetts bankruptcy attorney.
Business owner John Ceci has filed one of three lawsuits where federal courts have recently ruled. The U.S. Supreme Court is actually reviewing the health-care law next week to figure out if it is constitutional.
The fact is, health care is extremely expensive in America and those who are uninsured are taking a gamble, proponents of the mandate claim. An unexpected illness or accident could result in six-figure bills in a short period of time.
Even the insured have been hit lately with unexpected out-of-network charges. The Department of Financial Services (DFS) in New York recently released a report stating that insurance companies and healthcare providers are to blame for these unexpected expenses, which have forced many people to file for bankruptcy. The DFS is recommending more transparency in the breakdown of charges a patient is actually responsible for so the patient can make the best decision for treatment options.
Out-of-pocket healthcare expenses are on an upswing around the board. In the latest survey conducted through the National Center for Health Statistics, many Americans claimed they usually have trouble paying their medical bills. This Season, 20 percent of American families struggled. In the first part of 2011, the amount grew to one in three families struggling to pay off their medical bills. With increasing price of healthcare, insurers are confronted with the choice of raising premiums or passing off many of the expenses to the customer. More than 50 % of personal bankruptcies are brought on by medical bills and roughly two-thirds of Americans in cases like this actually had insurance. This debunks the idea that forcing everyone to get insured helps save people from financial ruin. Experts caution that in case you actually are insured, make certain to know your policy inside and out and also always seek in-network care first. And while deciding on a less expensive plan might cost less money for the short-term, an urgent medical event could leave you in a massive amount of debt down the road. Regardless, shouldn?t people be allowed to make the choice for themselves rather than big government deciding on their behalf?
Law Offices of Kaplan Attorneys is a professional corporation located in Stoughton, Massachusetts that provides quality legal services in the areas of Bankruptcy Law, Divorce and Family Law and Real Estate Law in most counties in the Commonwealth of Massachusetts. Tag: Boston bankruptcy lawyers
?Mail this post 
unlv sam young ncaa bracket ramon sessions portland trail blazers nba trade blagojevich
French intel chief: detained Islamists a threat
[ [ [['A JetBlue flight from New York to Las Vegas', 3]], 'http://yhoo.it/GV9zpj', '[Related: View photos of the JetBlue plane in Amarillo]', ' ', '630', ' ', ' ', ], [ [['Afghan security forces and police killed three', 3]], 'http://yhoo.it/H9BcJE', '[Related: Bales\' wife on his alleged shooting: \'He would not do that\']', ' ', '630', ' ', ' ', ], [ [['looking for fireworks between the opposing camps', 16]], 'http://yhoo.it/GSvEsj', '[RELATED:\?It?s going to be a circus\?: Activists begin protests outside Supreme Court]', ' ', '630', ' ', ' ', ], [ [['entirely respectable way to put off the searing constitutional controversy', 8]], 'http://yhoo.it/GE6jSh', '[RELATED: Obama\?s health care law passed 2 years ago, but where are we now\?]', ' ', '630', ' ', ' ', ], [ [['Witnesses said the gunman pulled up on a black scooter', 7]], 'http://yhoo.it/GzwOIW', '[Related: New York police tighten security at Jewish sites]', ' ', '630', ' ', ' ', ], [ [['test Zimmerman for alcohol or drugs', 11]], 'http://yhoo.it/Gzn6VF', '[Related: White House says Trayvon Martin is local issue]', ' ', '630', ' ', ' ', ], [ [['Trayvon Martin decked the Neighborhood', 7]], 'http://yhoo.it/GUovUP', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/2/61/261d2c36bccf0971c2734a4d4398aa5a.jpeg', '512', ' ', 'AP/David Goldman', ], [ [['Can you create commerce in order to regulate it', 9]], 'http://yhoo.it/GSgtu8', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/7/78/778e2416573870cd705774e92403447d.jpeg', '630', ' ', 'AP/Charles Dharapak', ], [ [['associated with such a small earthquake', 4]], 'http://yhoo.it/GTco9z', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/0/b4/0b493c1a47b6e3f97f8f48a2b251d7d4.jpeg', '630', ' ', 'AP Photo/Carrie Antlfinger', ], [ [['Fox News host Geraldo Rivera sparked outrage', 3]], 'http://yhoo.it/GKMVTk', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/2/7c/27c7367bc512d233ae1790b320a5e92c.jpeg', '630', ' ', 'AP Photo/John Minchillo', ], [ [['The charges signed against Bales include', 1]], 'http://yhoo.it/wZT5zV', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/7/a0/7a07c51b2aa0f39b1a23355046d13870.jpeg', '512', ' ', 'AP Photo/DVIDS\, Spc\. Ryan Hallock\, File', ], [ [['George Zimmerman, if I had a son', 6]], 'http://news.yahoo.com/photos/thousands-protest-fla-teen-death-1332387124-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/os/152/2012/03/22/d761a49f3fcc99080a0f6a70670053cd-jpg_150905.jpg', '500', ' ', 'AP Photo/John Minchillo', ], [ [['Mohamed Merah', 10], ['prosecutor Francois Molins', 5]], 'http://news.yahoo.com/photos/four-dead-in-french-jewish-school-shooting-1332173151-slideshow', 'Click image to see more photos', 'http://l.yimg.com/cv/ip/ap/default/120321/2012_03_21t151508z_425380421_gm1e83l1sqs01_rtrmadp_3_france_shootings_raid.jpg', '630', ' ', 'REUTERS/Jean-Paul Pelissier', ], [ [['Shortly after he wrapped up his victory remarks', 2]], 'http://news.yahoo.com/photos/4-straight-romney-wins-washington-gop-caucus-1330835515-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/3/e9/3e9b0082c3c3111dcc19e3527ae94cc7.jpeg', '500', ' ', 'AP Photo/Steven Senne', ], [ [['best understands the problems of average Americans', 2]], 'http://news.yahoo.com/photos/4-straight-romney-wins-washington-gop-caucus-1330835515-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/3/e9/3e9b0082c3c3111dcc19e3527ae94cc7.jpeg', '500', ' ', 'AP Photo/Steven Senne', ], [ [['Group for Historic Aircraft Recovery', 7]], 'http://yhoo.it/GB2RVy', 'Click image to see more photos', 'http://l.yimg.com/os/152/2012/03/20/photo-1332257995646-4-0-jpg_171722.jpg', '630', ' ', 'AFP', ], [ [['xxxxxxxxxxxx', 11]], 'http://news.yahoo.com/photos/russian-grannies-win-bid-to-sing-at-eurovision-1331223625-slideshow/', 'Click image to see more photos', 'http://l.yimg.com/a/p/us/news/editorial/1/56/156d92f2760dcd3e75bcd649a8b85fcf.jpeg', '500', ' ', 'AP', ] ]
[ [ [['measure all but certain to fail in the face of bipartisan', 4]], '28771014', '0' ], [ [['matter what you do in this case', 5]], '28759848', '0' ], [ [['presume laws are constitutional', 7]], '28747556', '0' ], [ [['has destroyed 15 to 25 houses', 7]], '28744868', '0' ], [ [['short answer is yes', 7]], '28746030', '0' ], [ [['opportunity to tell the real story', 7]], '28731764', '0' ], [ [['entirely respectable way to put off the searing constitutional controversy', 7]], '28723797', '0' ], [ [['point of my campaign is that big ideas matter', 9]], '28712293', '0' ], [ [['As the standoff dragged into a second day', 7]], '28687424', '0' ], [ [['French police stepped up the search', 17]], '28667224', '0' ], [ [['Seeking to elevate his candidacy back to a general', 8]], '28660934', '0' ], [ [['The tragic story of Trayvon Martin', 4]], '28647343', '0' ], [ [['Karzai will get a chance soon to express', 8]], '28630306', '0' ], [ [['powerful storms stretching', 8]], '28493546', '0' ], [ [['basic norm that death is private', 6]], '28413590', '0' ], [ [['songwriter also saw a surge in sales for her debut album', 6]], '28413590', '1', 'Watch music videos from Whitney Houston ', 'on Yahoo! Music', 'http://music.yahoo.com' ], [ [['keyword', 99999999999999999999999]], 'videoID', '1', 'overwrite-pre-description', 'overwrite-link-string', 'overwrite-link-url' ] ]
martin henderson mlk day golden globes 2012 winners golden globes 2012 red carpet golden globes red carpet nfc championship game martin luther king jr quotes
Larry Echo Hawk appointed to LDS Church leadership
SALT LAKE CITY (AP) ? A top official for the U.S. Bureau of Indian Affairs is resigning to accept a leadership position with The Church of Jesus Christ of Latter-day Saints.
Assistant Secretary Larry Echo Hawk is being appointed to the Quorum of the Seventy, which is the Mormon Church's third-highest governing body. It is a full-time position.
The 63-year-old Echo Hawk is a member of the Pawnee Nation. He has worked for Indian Affairs since 2009.
Echo Hawk was elected as the attorney general for Idaho in 1990, the first Native American in the country to be elected as a state attorney general. He ran unsuccessfully as a Democrat in 1994 for governor of Idaho.
The appointment was announced Saturday during the Mormon Church's semi-annual general conference in Salt Lake City.
?2012 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
david nelson david nelson frank miller 60 minutes oobleck justin timberlake marine corps ball frank gore injury
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uATMwjhxaxlyCohsLzuwpMrwMv9gKniHZDgvrM_1cH-rm0ZGDpSuuVKyyepVPTqFstOSvLGlgBBEpWoWoKj8RTfIAqLSYk7wb1Js1oNL8=s0-d){kind=small}
Public release date: 31-Mar-2012[ | E-mail |
Share ] Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Phase 1 data presented at AACR Annual Meeting 2012; Study showed no dose limiting toxicities with galeterone; Preliminary efficacy data reported
CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy nave patients with castration-resistant prostate cancer (CRPC)," abstract number CT-07, on Tuesday, April 3, 2012 at 3:05 p.m. (CDT) at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.
CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of anti-hormonal therapies. Galeterone is a small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel and proprietary triple mechanism of action.
"Because currently available therapeutic options to treat castration-resistant prostate cancer are limited, often poorly-tolerated and may fail because of resistance, patients are in urgent need of new safe and effective treatments," said Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School and co-lead researcher in the study. "These Phase 1 galeterone data, demonstrating minimal toxicities, improved PSA response and a reduction in tumor size, are exciting for those of us in the medical community treating this life-threatening cancer. I look forward to following the further development of galeterone as a promising approach in the treatment of prostate cancer."
The ARMOR1 study was led by co-principal investigators Dr. Taplin and Bruce Montgomery, M.D., associate professor of medical oncology at the University of Washington School of Medicine, and their colleagues at leading prostate cancer research centers in the United States. The Phase 1 proof-of-concept clinical trial, part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program for the evaluation of galeterone, enrolled 49 patients and was a dose-finding study to evaluate escalating dose levels of galeterone. The study also evaluated safety and reduction in prostate-specific antigen (PSA) levels from baseline levels measured at first visit. Patients who responded to therapy had the option to continue treatment with galeterone in an extension arm of the trial.
Most side effects were minor and included fatigue, nausea and diarrhea. Early efficacy tests demonstrated that 49 percent of patients had prostate-specific antigen (PSA) reductions of 30 percent or more; 11 of these patients had reductions of 50 percent or more. In addition, CT scans revealed a significant reduction in tumor size for some patients.
"We are pleased with the results of our Phase 1 proof-of-concept study, which demonstrated galeterone tolerability and efficacy in a difficult-to-treat, resistant prostate cancer patient population," said Martin D. Williams, president and chief executive officer, Tokai Pharmaceuticals. "Galeterone is the only prostate cancer therapy in development that combines three distinct mechanisms of action in one compound for a unique multi-target approach. The reductions in PSA levels seen in nearly half of all patients evaluated in our Phase 1 study are meaningful in a dose-escalation study and supportive of our Phase 2 clinical trial set to initiate later this year."
In the Phase 1 study, researchers observed transient, non-serious elevated liver function tests in 15 patients, most of whom were asymptomatic. Eleven of these patients stopped galeterone treatment, and of those, six of seven patients were rechallenged and successfully returned to treatment with no significant recurrence in liver function test elevations.
A Phase 2 study evaluating long-term safety and efficacy of galeterone in CRPC patients is planned for the second half of 2012.
###
About Galeterone (TOK-001)
Galeterone is a small molecule, oral drug for the treatment of prostate cancer that disrupts the growth and survival of cancer cells via a novel and proprietary triple mechanism of action. In preclinical studies, galeterone acts as an androgen receptor antagonist, as a CYP17 lyase inhibitor and decreases androgen receptor levels in prostate tumors the only drug in development that has been shown to exhibit this property. In galeterone, these three distinct mechanisms of action are combined in one therapy.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company's lead drug candidate, galeterone (TOK-001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic. Privately held Tokai is based in Cambridge, Massachusetts and is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visit www.tokaipharma.com.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 31-Mar-2012[ | E-mail |
Share ] Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Phase 1 data presented at AACR Annual Meeting 2012; Study showed no dose limiting toxicities with galeterone; Preliminary efficacy data reported
CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy nave patients with castration-resistant prostate cancer (CRPC)," abstract number CT-07, on Tuesday, April 3, 2012 at 3:05 p.m. (CDT) at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.
CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of anti-hormonal therapies. Galeterone is a small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel and proprietary triple mechanism of action.
"Because currently available therapeutic options to treat castration-resistant prostate cancer are limited, often poorly-tolerated and may fail because of resistance, patients are in urgent need of new safe and effective treatments," said Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School and co-lead researcher in the study. "These Phase 1 galeterone data, demonstrating minimal toxicities, improved PSA response and a reduction in tumor size, are exciting for those of us in the medical community treating this life-threatening cancer. I look forward to following the further development of galeterone as a promising approach in the treatment of prostate cancer."
The ARMOR1 study was led by co-principal investigators Dr. Taplin and Bruce Montgomery, M.D., associate professor of medical oncology at the University of Washington School of Medicine, and their colleagues at leading prostate cancer research centers in the United States. The Phase 1 proof-of-concept clinical trial, part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program for the evaluation of galeterone, enrolled 49 patients and was a dose-finding study to evaluate escalating dose levels of galeterone. The study also evaluated safety and reduction in prostate-specific antigen (PSA) levels from baseline levels measured at first visit. Patients who responded to therapy had the option to continue treatment with galeterone in an extension arm of the trial.
Most side effects were minor and included fatigue, nausea and diarrhea. Early efficacy tests demonstrated that 49 percent of patients had prostate-specific antigen (PSA) reductions of 30 percent or more; 11 of these patients had reductions of 50 percent or more. In addition, CT scans revealed a significant reduction in tumor size for some patients.
"We are pleased with the results of our Phase 1 proof-of-concept study, which demonstrated galeterone tolerability and efficacy in a difficult-to-treat, resistant prostate cancer patient population," said Martin D. Williams, president and chief executive officer, Tokai Pharmaceuticals. "Galeterone is the only prostate cancer therapy in development that combines three distinct mechanisms of action in one compound for a unique multi-target approach. The reductions in PSA levels seen in nearly half of all patients evaluated in our Phase 1 study are meaningful in a dose-escalation study and supportive of our Phase 2 clinical trial set to initiate later this year."
In the Phase 1 study, researchers observed transient, non-serious elevated liver function tests in 15 patients, most of whom were asymptomatic. Eleven of these patients stopped galeterone treatment, and of those, six of seven patients were rechallenged and successfully returned to treatment with no significant recurrence in liver function test elevations.
A Phase 2 study evaluating long-term safety and efficacy of galeterone in CRPC patients is planned for the second half of 2012.
###
About Galeterone (TOK-001)
Galeterone is a small molecule, oral drug for the treatment of prostate cancer that disrupts the growth and survival of cancer cells via a novel and proprietary triple mechanism of action. In preclinical studies, galeterone acts as an androgen receptor antagonist, as a CYP17 lyase inhibitor and decreases androgen receptor levels in prostate tumors the only drug in development that has been shown to exhibit this property. In galeterone, these three distinct mechanisms of action are combined in one therapy.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company's lead drug candidate, galeterone (TOK-001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic. Privately held Tokai is based in Cambridge, Massachusetts and is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visit www.tokaipharma.com.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
there will be blood extreme makeover home edition friday the 13th jimmy fallon jimmy fallon michael pineda coachella 2012
Apple needs to redefine itself, but that shouldn't take long
[Thanks, Ishmaeel]
Apple needs to redefine itself, but that shouldn't take long originally appeared on Engadget on Fri, 30 Mar 2012 11:25:00 EDT. Please see our terms for use of feeds.
Permalink | | Email this | Commentstaylor allderdice vincent jackson vicki gunvalson brandon marshall pierre garcon brown recluse spider wiz khalifa taylor allderdice
Online Marketing News - Internet Marketing University of Canada
Online Marketing News: Facebook Timeline is Here, State of the News Media, Google Cracks Down
Become a Certified Internet Marketing Professional at the Internet Marketing University of Canada
Small Businesses Increase Online Marketing Efforts
This video from AT&T Business provides great insight into online marketing trends for small businesses. ?What you?ll learn:
- User preferences
- Network Growth
- Online Marketing Tactics
News You Can Use
?Don?t Dread Tomorrow?s Mandatory Switch to Timeline, Study Shows It?s Good for 95% of Facebook Pages? ?March 30 marks the official rollout of Timeline for Facebook business Pages. ?This change has many business owners and brands up in arms. ?However according to a recent study 95% of Pages who have switched to the Timeline have seen an increase of likes and buzz about their business. ?Via TechCrunch.
?Google Cracking Down on ?Unnatural? Links, Deindexing Blog Networks? ?Falling from Google?s graces, a position that no company wants to see themselves in. ?Recent shifts in Google?s policies include the way that Google perceives inbound links. ?Via Search Engine Watch.
?The State of the News Media 2012 ? Pew Research Center? ?This recent study contained some interesting findings about the current state of media and customers. ?Mobile is a driving force for customer experience with news information. ?Social media is still maintaining popularity, but is not an overwhelming means of driving traffic.? ?Via State of the Media.
?Pining for Pinterest? ?Should Pinterest be a key piece to your Internet marketing strategy? ?This post provides some great information that is not only focused on getting started, but ways to create meaningful interactions with your audience which drive results. ?Via ClickZ.
?8 Creative Ways to Use Embeddable Tweets? Embedded tweets allow users to take information from a tweet and share it on their website or even a blog post. ?This new feature from Twitter will enable users to share their information with an audience outside of their direct Twitter connections. ?Via Social Media Examiner.
TopRank Team News
Brian Larson- Even with a #1 Organic Ranking, Paid Ads Provide 50% Incremental Clicks
Google released a study that found that those who invested paid search received material increases in the number of clicks to their site. But the online marketers world needed more proof. Now, Google has provided that proof and more. For those who see paid and organic as 2 different worlds, I encourage you to give this a read. ?Via Search Engine Land.
Shawna Kenyon- Beyond Likes: ?How Google and Adobe Aim to Measure Your True Social ROI
Social Media has muddied the waters in terms of measuring traditional ?marketing spending?. It is no longer about sinking money into an ad campaign and then looking to see if sales increased. Now we measure success in ways that go beyond tangible impact. Did a campaign add an increase in Facebook likes? And if so is that an effective use of your budget? ?Google and Adobe want to answer that question by releasing tools that let marketers track their marketing spend through social media. ?Via Mashable.
Sam Giehll ? Mind Control: Neuroscience in Marketing
This article addresses a new field out there: neuromarketing. The idea of neuromarketing is that knowledge of neuroscience and the way the brain works from a scientific viewpoint is something that can be beneficial to marketers. Neuromarketing practices include studying consumers? sensimotor, cognitive and affective responses to different marketing stimuli. ?Via Psychology Today.
Alexis Hall ? Keyword Not Provided Percentage to Grow: ?Firefox Adding Default Encryption for Google Searches
Mozilla announced?last week that they are testing defaulting encrypted Google searches from their Firefox browser.? Currently, about 25% of all searches are done from Firefox, so this change could have a big impact on the percentage of keyword encrypted searches we are seeing within Google Analytics. As this percentage continues to increase it will become increasingly important to examine the data that you do have, such as top content.? ?Via Search Engine Journal.
Jolina Pettice ? What Happens in an Internet Minute?
In the time it takes you to pour your next cup of coffee, consider this activity happening on the Internet:?204 Emails Sent,?47,000 apps downloaded,?2+ million Google Search Queries,?6 million Facebook views. ?Check this infographic from Intel explaining What Happens in an Internet Minute. ?Via Intel.
Time to Weigh In: ?Have the recent shifts made by Google had a noticeable impact on your online visibility? ?Do you believe that Twitters new embed option will really make a difference, and how do you see your organization using this information?
Gain a competitive advantage by subscribing to the
TopRank? Online Marketing Newsletter.
? Online Marketing Blog, 2012. |
Online Marketing News: Facebook Timeline is Here, State of the News Media, Google Cracks Down | http://www.toprankblog.com
Become a Certified Internet Marketing Professional at the Internet Marketing University of Canada
new jersey weather halloween movies halloween movies new york snow new york snow braxton miller braxton miller